Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001044932 | SCV001208756 | benign | Amyotrophic lateral sclerosis type 4; Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2 | 2024-01-18 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV002261259 | SCV002541025 | uncertain significance | not provided | 2022-01-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002409408 | SCV002675783 | likely benign | Inborn genetic diseases | 2022-07-14 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Revvity Omics, |
RCV002261259 | SCV004237227 | uncertain significance | not provided | 2023-03-07 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004545025 | SCV004761755 | uncertain significance | SETX-related disorder | 2024-08-20 | no assertion criteria provided | clinical testing | The SETX c.7982A>G variant is predicted to result in the amino acid substitution p.Lys2661Arg. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.060% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |